NASDAQ · Dividend

MapLight Therapeutics, Inc. (MPLT) Dividend

$6.57 NASDAQ: MPLT Market Cap $280.00M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

MetricValue
Dividend YieldNone
Indicated Annual Dividend—
Payout Ratio—
FCF Yield-60.87%
Current Price$6.57

Dividend Analysis

MapLight Therapeutics, Inc. (MPLT) does not currently pay a dividend, based on the latest available data. Companies that do not pay dividends may use earnings for reinvestment, acquisitions, share buybacks, or debt repayment instead.

Free cash flow yield of -60.87% is below the 0.00% dividend yield, so the dividend is not fully covered by free cash flow at the current price.

Dividend yield against peers

MapLight Therapeutics, Inc. has the lowest dividend yield of the 9 companies compared here.

CompanyYieldP/EPrice
Regeneron Pharmaceuticals, Inc. (REGN)0.47%19.22$957.76
Vertex Pharmaceuticals Incorporated (VRTX)0.00%34.56$534.20
Moderna, Inc. (MRNA)0.00%—$206.80
Revolution Medicines, Inc. (RVMD)0.00%—$162.69
Roivant Sciences Ltd. (ROIV)0.00%—$38.71
Insmed Incorporated (INSM)0.00%—$121.86
United Therapeutics Corporation (UTHR)0.00%21.31$584.10
Incyte Corporation (INCY)0.00%55.62$119.09
MapLight Therapeutics, Inc. (MPLT)0.00%-1.27$6.57

MapLight Therapeutics, Inc. (MPLT) dividend — frequently asked questions

Does MapLight Therapeutics, Inc. (MPLT) pay a dividend?

No, MapLight Therapeutics, Inc. (MPLT) does not currently pay a dividend.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
MPLT Overview MPLT Financials Screen Dividend Stocks

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.